# Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Source: https://onco.cc/trials/nct07346144/  
OnCo record `nct07346144` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TGX-007 in glioma & glioblastoma, run by Trogenix ltd, now recruiting.

## Summary

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma is a phase 1/2 interventional study registered as NCT07346144 by Trogenix ltd, with 68 participants planned, started 2026-04-21 and due to reach its primary completion in 2030-03. Interventions recorded: TGX-007 and Valaciclovir.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07346144
- Phase: 1/2
- Setting: A Phase I/II Study of an AAV-1 Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
- Sponsor: Trogenix ltd
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT07346144: https://clinicaltrials.gov/study/NCT07346144

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07346144.json